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Abstract
The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous 
coronary intervention (PCI) remains an important clinical question in interven-
tional cardiology. Several clinical and angiographic variables are associated with an 
increased risk for thrombotic events, and prolonged DAPT duration may improve 
long term clinical outcome. However, some patients also present high bleeding risk 
(HBR) characteristics and may require a shorter DAPT duration. The guidelines 
recommendations consider the data from randomized clinical trials, however 
numerous exclusion criteria may create gaps in the evidence leading to uncertain-
ties, the need for expert opinion and patient level decision making. Furthermore, 
the stent platforms have evolved in such way that opportunities now exist to shorten 
duration of DAPT. This chapter will review the variables associated with ischemic 
and bleeding risks as well as different stent platforms to help clinicians optimize 
DAPT duration in patients undergoing PCI.
Keywords: percutaneous coronary intervention, stents, acute coronary syndrome, 
high bleeding risk, duration of antiplatelet therapy
1. Introduction
The optimal antiplatelet therapy after percutaneous coronary intervention (PCI) 
remains an unanswered clinical question. The last 25 years of clinical investigations 
has mainly been focused on the choice of P2Y12 agents and on treatment duration. 
Initially, the observation that bare metal stents (BMS) implantation could be associ-
ated with thrombosis, and, subsequently, the observation that first-generation drug 
eluting stents (DES) were associated with very-late thrombosis risk led to studies 
evaluating prolonged duration regimens of DAPT after PCI, but also to innovations 
in stent technology. However, the newer, more potent drugs (prasugrel and ticagre-
lor) and the advent and evolution of modern second- and third-generation DES 
dramatically dwindled the incidence of late and very late thrombotic complications. 
Thus, interest has shifted in trying to find the optimal, shortened DAPT treatment 
to prevent the early thrombotic complications while avoiding the late hemorrhagic 
events, the latter being associated with a similar risk of all-cause mortality than 
post-PCI recurrent myocardial infarctions [1].
Numerous trials attempted to answer these important questions, sometimes lead-
ing to discrepant results. This chapter will focus on the current evidence listed on 
the guidelines of main scientific societies for three groups of patients: elective PCI, 
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PCI in the setting of acute coronary syndromes (ACS), and PCI for patients with 
a coexisting indication of oral anticoagulation (OAC). For each of them we will high-
light the standard recommendations for DAPT duration, as well as the main clinical, 
angiographic and stent-derived variables that should be used in the decision-making 
process to tailor a shortened DAPT therapy reflecting each patient need.
2. Latest guidelines on the topic
This document will include the latest recommendations of Canadian, American 
and European guidelines. Canadian scientific societies published two documents in 
2018 addressing antithrombotic treatment: The Canadian Cardiovascular Society 
(CCS)/Canadian Association of Interventional Cardiology focused update for the 
use of antiplatelet therapy [2] and the CCS focused update for the management 
of atrial fibrillation [3]. The American College of Cardiology/American Heart 
Association (ACC/AHA) published a focused update on the duration of DAPT 
in patients with coronary artery disease (CAD) in 2016, [4] while a recent AHA/
ACC/Heart Rhythm Society (HRS) focused update in the management of patients 
with atrial fibrillation was published in 2019 [5]. Lastly, the European Society of 
Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS) 
published a focused update on DAPT in 2017 [6]. However, the most recent 2020 
ESC guidelines for management of ACS in patients presenting without persistent 
ST-segment elevation [7] and 2020 ESC/EACTS guidelines for the management of 
atrial fibrillation [8] will also be reviewed. A dedicated, critical comparison of the 
available guidelines on DAPT was published previously this year [9].
3. Evaluation of bleeding and thrombotic risk
In order to tailor optimal DAPT duration, many variables must be taken into 
account to ensure adequate thrombotic protection while avoiding hemorrhagic 
complications. To that extent, different risk scores have been derived and validated.
The PARIS risk score was one of the first tools intended to predict risks for 
out-of-hospital events directly modified by prolonging DAPT beyond one year (i.e. 
coronary thrombosis and bleeding) [10]. The aim of the DAPT score is to identify 
patients expected to derive benefit or harm from continuing P2Y12 beyond 1 year. To 
that extent, data was gathered among patients that had not experienced any major 
ischemic or bleeding event 12 months after the index procedure [11]. Similarly, 
the CALIBER score includes patients surviving 12 months after a MI, including 
those not treated with PCI [12]. Hence, these three risk scores help establishing the 
security of long term DAPT duration.
In contrast, the PRECISE-DAPT score [13] assesses the benefit of a short 
(3–6 month) versus a long (12–24 month) DAPT duration. Furthermore, it allows 
clinicians to select DAPT duration upfront instead of at another point in time 
during follow-up. Of note, patients with the need of OAC were excluded from the 
derivation cohort. Patients undergoing elective, urgent and emergent PCI were all 
included in the analysis. At the time of the index PCI, an additive score is calculated 
by means of the presence of five clinical and biochemical variables (age, creatinine 
clearance, hemoglobin, white blood cell count and prior spontaneous bleeding), 
ranging 0 to 100 points. Patients ≥25 points were considered high bleeding risk 
(HBR), while <25 points were defined as non-HBR. Among HBR patients based 
on this score, prolonged DAPT contributed to no significant ischemic benefit, 
while, on the other hand, led to an increased risk of bleeding (number to harm 
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(NNH) = 38). In parallel, non-HBR patients benefited of a longer DAPT regimen in 
the form of a significant reduction in the composite endpoint of myocardial infarc-
tion (MI), definite stent thrombosis, stroke and target vessel revascularization 
(NNT for benefit of 68), with no significant increase in bleeding risk [13]. Results 
were consistent across the full spectrum of indications for PCI.
Some works have compared the accuracy of these scores head-to-head, in 
general showing little to no difference in their ability to predict bleeding [14–16].
More recently, the new ARC-HBR criteria have been validated at identifying 
patients at high bleeding risk, being more sensitive than the PRECISE-DAPT and 
PARIS risk scores (at the expense of specificity) [17]. Trials where these criteria are 
used to compare different antiplatelet durations are awaited.
It is worth noting, however, that no prediction model has been prospectively 
tested in the setting of a RCT.
On the other side of the coin, clinicians should be aware of certain clinical and 
angiographic features associated with a higher thrombotic risk in some patients, 
thus making it unadvisable to shorten their antiplatelet regimens. These character-
istics are summarized in Table 2.
4. Evidence for DAPT duration after PCI in non-ACS setting
Many trials have demonstrated the non-inferiority of 6-month versus longer 
treatment duration amid “all-comer” patients undergoing PCI for stable and ACS 
settings, [18–22] and so the recommendations for elective PCI are extrapolated for 
the aggregated results. The ACC and ESC guidelines give strong recommendations 
on a standard 6-month duration of DAPT in stable patients. As for the CCS, it places 
greater emphasis on reduction of major CV thrombotic events vs. an increase in 
bleeding complications, by recommending DAPT duration from 6 up to 12 months. 
(Table 1) This is due to some metanalysis showing increased risk of ischemic out-
comes with shorter DAPT durations in certain groups with high risk angiographic 
features (Table 2) [24–26].
All three guidelines suggest considering a 3-month DAPT course in patients at 
HBR. This comes from the experience of two trials where a zotarolimus-eluting 
stent was tested [27, 28]. However, due to the fact that this platform is no longer 
available, the recommendation stands at a weak level of evidence. The ESC guide-
lines also include the possibility of a 1-month period of DAPT in patients in whom 
3-month DAPT poses safety concerns. This recommendation comes from two trials 
in which a zotarolimus-eluting Endeavor sprint stent or Biofreedom drug-coated 
stent reduced ischemic endpoints compared to bare-metal stent under similar DAPT 
duration [29, 30].
Since their publication, some new evidence supports aspirin-free strategies 
early after PCI: the TWILIGHT trial included high risk patients who had not had an 
ischemic or bleeding event after a three-month course of aspirin plus ticagrelor and 
randomized them to aspirin or placebo for one year. Patients with ticagrelor mono-
therapy had a lower clinically relevant bleeding incidence while providing no higher 
death or ischemic endpoints [31]. The SMART-CHOICE randomized patients to 
receive aspirin plus a P2Y12 inhibitor for 3 months and thereafter a P2Y12 inhibitor 
alone or DAPT por 12 months. The monotherapy arm resulted in noninferior rates 
of major adverse cardiac events [32].
The GLOBAL LEADERS trial assessed the combination of ticagrelor and aspirin 
for one month followed by ticagrelor alone for 23 month versus 12 months of stan-
dard DAPT followed by 12 month of aspirin alone, with neutral results [33]. Later, 

















Grade of recommendation DAPT duration Grade of 
recommendation
DAPT duration Grade of 
recommendation





6–12 months Strong recommendation, 
moderate-quality evidence









Class IIb, level C-LD 3 months (HBR) Class IIa, level B
1 month (if bleeding safety 
concern with 3-month 
DAPT)
Class IIb, level C





12 months Strong recommendation, 
high-quality evidence
12 months Class I, level B-R 12 months Class I, level A
Minimal 
duration
12 months Strong recommendation, 
high-quality evidence
6 months Class IIb, level C-LD 3 months (HBR) Class IIa, level B
3–6 months, depending 
on ischemic/bleeding risk 
balance
Class IIa, level A
Table 1. 
Standard and shortened DAPT duration according to different guidelines. Adapted and updated from [9].
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of shortened DAPT arm in a selected subpopulation of the 20 highest recruiting 
sites of the main trial [34]. On the other hand, the STOPDAPT-2 trial showed the 
benefit of 1 month of aspirin plus clopidogrel followed by clopidogrel monotherapy 
vs. 12 month of standard DAPT, meeting the criteria for both noninferiority and 
superiority [35].
5. Evidence for DAPT duration after PCI in ACS setting
The three sets of guidelines provide strong recommendation for a standard 
12-month DAPT treatment after an ACS, based on the CURE trial and the PCI-
CURE substudy published nearly two decades ago, in which DAPT with aspirin 
and clopidogrel was prescribed for 3 to 12 months after PCI [36, 37]. More recently, 
the pivotal prasugrel and ticagrelor trials, conducted in patients with ACS, used a 
12-month default DAPT duration, furthermore establishing this approach as the 
standard of practice (Table 1) [38, 39].
5.1 Scenarios for shortened DAPT
Due to the time gap between the latest ESC guidelines on this topic and its 
American and Canadian counterparts, recommendations on minimal DAPT 
duration differ between the former and the latter (Table 1). The scarce evidence 
available at the time of the last ACC/AHA and CCS guidelines led to only weak 
recommendation for a 6-month DAPT on the former, while the latter holds at a 
12-month recommendation. This year’s ESC guidelines on the management of ACS 
in patients presenting without persisting ST-segment elevation includes various 
guidance on short DAPT.
As discussed previously, the insight from the PRECISE-DAPT study led to 
consider a shortened 3-month DAPT duration in patients at HBR (PRECISE-DAPT 
score ≥ 25) (Recommendation IIa B) [13]. What is probably more interesting, 
however, is the evidence gathered recently on patients at low-to-intermediate 
ischemic risk and low bleeding risk. The previously described TWILIGHT and 
SMART-CHOICE trials included a high proportion of patients presenting with ACS 








Implantation of ≥3 stents [24]
Stented length (>60 mm) [24]
Complex lesions (bifurcation, chronic total occlusion) [24]
Left main or left anterior descending stenting [25]
Multivessel stenting [26]
Table 2. 
High risk features associated with thrombotic events. Adapted from [3].
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being consistent between subgroups. On the other hand, the SMART-DATE trial 
[40] specifically assessed 6 versus 12-month DAPT in patients with ACS. Although 
mortality, stroke and BARC type 2–5 bleeding did not differ between the two 
groups, the rate of myocardial infarction was higher in the short DAPT group. 
Combining the information of these three trials, the ESC guidelines suggest a 3 to 
6-month DAPT therapy depending on the balance of ischemic and hemorrhagic 
risk in a Class IIa, level A recommendation. The recent TICO trial evaluated another 
aspirin-free strategy, specifically among patients undergoing PCI for an ACS [41]. 
Ticagrelor monotherapy after 3 months of DAPT resulted in a slight, significant 
reduction of the composite outcome of major bleeding and cardiovascular events at 
one year, compared with a ticagrelor-based 12-month DAPT.
6.  Evidence of shortened DAPT duration in patients after PCI requiring 
lifelong oral anticoagulation
The landscape of evidence for the treatment of patients requiring lifelong oral 
anticoagulation after PCI has expanded notably in the last years, the main land-
marks being (1) the ISAR-TRIPLE trial, where no significant difference was found 
in the primary endpoint of “net clinical benefit” (which included ischemic and 
bleeding outcomes) between 6 weeks and six months of triple therapy; [42] (2) 
the WOEST trial, where a dual pathway strategy (warfarin and clopidogrel) versus 
standard triple therapy (warfarin, clopidogrel and ASA) reduced bleeding while 
not increasing thrombotic events; [43] and (3) the advent of the new four direct 
oral anticoagulants (DOAC) and their specific trials for patients undergoing PCI, 
AF patients with ACS/PCI
Clinical setting Therapy regimen Recommendation
Uncomplicated or bleedinga > 
ischemicb risk
• TT < 1 week
• OAC + P2Y12 (preferably clopidogrel) 
up to 12 months
I B
Ischemicb > bleedinga risk • TT > 1 week and ≤ 1 month
• OAC + P2Y12 (preferably clopidogrel) 
up to 12 months
IIa C
AF patients with CCS undergoing PCI
Clinical setting Therapy regimen Recommendation
Uncomplicated or bleedinga > 
ischemicb risk
• TT ≤ 1 week
• OAC + P2Y12 (preferably clopidogrel) 
up to 6 months
I B
Ischemicb > bleedinga risk • TT > 1 week and ≤ 1 month
• OAC + clopidogrel up to 12 months
IIa C
aEvaluation based on HAS-BLED score: Hypertension, Abnormal renal or liver function, Stroke or ICH history, 
Bleeding history or bleeding diathesis, Labile INR, Elderly (>65 years), Drugs (concomitant OAC and antiplatelet 
therapy, NSAIDs).
bEvaluation based on (1) clinical factors: diabetes, prior ACS, multivessel CAD, concomitant peripheral artery 
disease, premature or accelerated CAD, chronic kidney disease, ACS as clinical presentation; (2) anatomical factors: 
multivessel stenting, complex stenting (left main or last patent vessel stenting, chronic total occlusion intervention), 
prior stent thrombosis on antiplatelet treatment.
TT: Triple therapy; CCS: chronic coronary syndrome.
Table 3. 
Recommendations for antithrombotic patients of AF patients undergoing PCI. Adapted from the 2020 ESC 
ESC/EACTS guidelines for the management of atrial fibrillation [8].
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[dabigatran/RE-DUAL PCI [44]; rivaroxaban/PIONEER AF-PCI [45]; apixaban/
AUGUSTUS [46]; edoxaban/ENTRUST-AF PCI [47]. The new 2020 ESC ESC/
EACTS guidelines for the management of atrial fibrillation is the latest consensus 
document on the subject, and the only one after the publication of the four DOAC 
trials for AF patients undergoing PCI [8].
As a whole, these trials evaluated dual (DOAC + P2Y12) vs. triple (VKA + 
P2Y12 + aspirin) therapy. They included a notable proportion of ACS (37–52%), 
although the highest risk patients were underrepresented (i.e., culprit lesions in 
a previously stented segment). Moreover, they all used triple therapy during PCI 
until randomization (1–14 days post PCI) and the most commonly P2Y12 inhibi-
tor used was clopidogrel, as neither prasugrel or ticagrelor have evidence sup-
porting their safety in combination with an OAC. As per outcomes, they reported 
a significant reduction of major/clinically significant bleeding, comparable rates 
of ischemic stroke, similar or non-significantly higher rates of myocardial infarc-
tion and stent thrombosis and a neutral effect on major adverse cardiac events 
and all-cause mortality [48]. Also, it is worth emphasizing that the AUGUSTUS 
trial is the only one that studied whether the advantages of dual pathway (vs. 
triple therapy) is independent of the type of OAC.
The ESC guidelines include four recommendations, according to the clini-
cal presentation and the ischemic/bleeding risk balance (Table 3). Due to the 
under-representation of high ischemic risk patients on the trials, the recom-
mendations for this population have a weak level of evidence. The evaluation of 
the ischemic risk is based on the presence of variables known to pose higher risk 
in the general population (also previously described in Table 2). Regarding the 
bleeding risk, evaluation with the AF-specific HAS-BLED risk score is recom-
mended. This bleeding risk score has proven to be more useful at predicting 
bleeding risk in AF patients [49].
7.  Beyond guidelines: tailored shortened DAPT durations according  
to stent platforms
Current guidelines include DAPT length recommendations irrespective of the 
DES type, encompassing the evidence of the multiple platforms in various trials. It is 
worth mentioning, however, some recent trials in which specific platforms have been 
tested in two main scenarios: one stent tested at short vs. longer DAPT durations; 
and two different stents compared in a short DAPT duration for patients not deemed 
amenable for prolonged DAPT duration. While acknowledging the limited value of a 
single trial, they may still be useful for tailored antiplatelet regimens. Table 4 sum-
marizes the current knowledge of some specific DES platforms in these two scenarios.
8. Conclusions
As new antiplatelet and anticoagulant drugs have entered the therapeutic 
arsenal, and as stent platforms continue to be refined through the years, established 
dogmas of the treatment of patients with ischemic heart disease should be reas-
sessed. Most notably, current evidence strongly supports that for a considerable 
number of patients, shorter antithrombotic, aspirin-free treatment is associated not 
only with fewer bleeding complications, but with comparable rates of hard ischemic 
endpoints. Hence, a paradigm shift is underway, in which the concern should not be 
to find reasons to reduce the classical 12 months of DAPT. Rather, patients should 
be evaluated for causes not to receive an abbreviated aspirin-free antithrombotic 
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(stable patients) or ASA/
ticagrelor (ACS) followed 
by ASA (1:1)
No superiority of 









Cobra stent vs. standard 
DES
Cobra: DAPT 14 days, 
then OAC + ASA until 
6 monts. Control stent: 
DAPT 3–6 monts. After 
6 months, all received 
OAC + ASA
Cobra PzF stents 
did not achieve 
bleeding reduction 
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relevant and 























3 month DAPT 
followed by ticagrelor 
monotherapy vs standard 
12 month DAPT
Modest reduction 
of bleeding and 
cardiovascular 
events.

























Resolute Onyx vs. 
Biofreedom (1:1)





in safety and 
effectiveness





Endeavor stent vs. ultra-
thin BMS (1:1)
1 month DAPT
Low risk of 
1-year MACE in 
Endeavor patients








Synergy stent vs. 
ultrathin BMS
1 month or 6 months 
DAPT, according to 
stable or unstable 
presentation
Low risk of 
ischemic 
endpoints in the 
Synergy arm
Table 4. 
Recent trials on the performance of different stent platforms on shortened DAPT scenarios.
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regimen. In order to provide the most accurate treatment regimens, a careful evalu-
ation should be made by taking into account the clinical presentation, coexisting 
conditions that are prone to a higher ischemic or bleeding risk and awareness of the 
stent platform used.
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